Browse GHR

Summary
SymbolGHR
Namegrowth hormone receptor
Aliases growth hormone binding protein; GHIP; GH receptor; serum binding protein; somatotropin receptor
Chromosomal Location5p14-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein. Note=On growth hormone binding, GHR is ubiquitinated, internalized, down-regulated and transported into a degradative or non-degradative pathway. ; SUBCELLULAR LOCATION: Isoform 2: Cell membrane; Single-pass type I membrane protein. Note=Remains fixed to the cell membrane and is not internalized.; SUBCELLULAR LOCATION: Growth hormone-binding protein: Secreted. Note=Complexed to a substantial fraction of circulating GH.
Domain PF09067 Erythropoietin receptor
PF00041 Fibronectin type III domain
PF12772 Growth hormone receptor binding
Function

Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway (By similarity). ; FUNCTION: The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.; FUNCTION: Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling.

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0000255 allantoin metabolic process
GO:0006101 citrate metabolic process
GO:0006103 2-oxoglutarate metabolic process
GO:0006105 succinate metabolic process
GO:0006107 oxaloacetate metabolic process
GO:0006520 cellular amino acid metabolic process
GO:0006549 isoleucine metabolic process
GO:0006573 valine metabolic process
GO:0006600 creatine metabolic process
GO:0006631 fatty acid metabolic process
GO:0006790 sulfur compound metabolic process
GO:0007259 JAK-STAT cascade
GO:0007260 tyrosine phosphorylation of STAT protein
GO:0009081 branched-chain amino acid metabolic process
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019530 taurine metabolic process
GO:0032147 activation of protein kinase activity
GO:0033674 positive regulation of kinase activity
GO:0035264 multicellular organism growth
GO:0040014 regulation of multicellular organism growth
GO:0040018 positive regulation of multicellular organism growth
GO:0042503 tyrosine phosphorylation of Stat3 protein
GO:0042506 tyrosine phosphorylation of Stat5 protein
GO:0042509 regulation of tyrosine phosphorylation of STAT protein
GO:0042516 regulation of tyrosine phosphorylation of Stat3 protein
GO:0042517 positive regulation of tyrosine phosphorylation of Stat3 protein
GO:0042522 regulation of tyrosine phosphorylation of Stat5 protein
GO:0042523 positive regulation of tyrosine phosphorylation of Stat5 protein
GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein
GO:0042976 activation of Janus kinase activity
GO:0042977 activation of JAK2 kinase activity
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043434 response to peptide hormone
GO:0043648 dicarboxylic acid metabolic process
GO:0044236 multicellular organism metabolic process
GO:0045860 positive regulation of protein kinase activity
GO:0045927 positive regulation of growth
GO:0046425 regulation of JAK-STAT cascade
GO:0046427 positive regulation of JAK-STAT cascade
GO:0046449 creatinine metabolic process
GO:0048009 insulin-like growth factor receptor signaling pathway
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0060396 growth hormone receptor signaling pathway
GO:0060397 JAK-STAT cascade involved in growth hormone signaling pathway
GO:0060416 response to growth hormone
GO:0071375 cellular response to peptide hormone stimulus
GO:0071378 cellular response to growth hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072338 cellular lactam metabolic process
GO:0072350 tricarboxylic acid metabolic process
GO:0097696 STAT cascade
GO:1901605 alpha-amino acid metabolic process
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1904892 regulation of STAT cascade
GO:1904894 positive regulation of STAT cascade
Molecular Function GO:0004896 cytokine receptor activity
GO:0017046 peptide hormone binding
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0042562 hormone binding
GO:0070064 proline-rich region binding
Cellular Component GO:0043235 receptor complex
GO:0070195 growth hormone receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04080 Neuroactive ligand-receptor interaction
hsa04151 PI3K-Akt signaling pathway
hsa04630 Jak-STAT signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-982772: Growth hormone receptor signaling
R-HSA-168256: Immune System
R-HSA-1170546: Prolactin receptor signaling
Summary
SymbolGHR
Namegrowth hormone receptor
Aliases growth hormone binding protein; GHIP; GH receptor; serum binding protein; somatotropin receptor
Chromosomal Location5p14-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GHR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolGHR
Namegrowth hormone receptor
Aliases growth hormone binding protein; GHIP; GH receptor; serum binding protein; somatotropin receptor
Chromosomal Location5p14-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GHR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGHR
Namegrowth hormone receptor
Aliases growth hormone binding protein; GHIP; GH receptor; serum binding protein; somatotropin receptor
Chromosomal Location5p14-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GHR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3760.453
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6780.44
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.150.101
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0570.904
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1790.906
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3470.836
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3240.575
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5780.6
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0170.989
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.6280.496
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4240.705
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4070.0342
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GHR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277322.24.118.10.011
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275922.25.117.10.0245
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.323.5-9.20.678
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)862516.78.31
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.727.3-19.60.3
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.314.8-9.50.224
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.521.4-8.90.642
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolGHR
Namegrowth hormone receptor
Aliases growth hormone binding protein; GHIP; GH receptor; serum binding protein; somatotropin receptor
Chromosomal Location5p14-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GHR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGHR
Namegrowth hormone receptor
Aliases growth hormone binding protein; GHIP; GH receptor; serum binding protein; somatotropin receptor
Chromosomal Location5p14-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GHR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GHR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGHR
Namegrowth hormone receptor
Aliases growth hormone binding protein; GHIP; GH receptor; serum binding protein; somatotropin receptor
Chromosomal Location5p14-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GHR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGHR
Namegrowth hormone receptor
Aliases growth hormone binding protein; GHIP; GH receptor; serum binding protein; somatotropin receptor
Chromosomal Location5p14-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GHR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGHR
Namegrowth hormone receptor
Aliases growth hormone binding protein; GHIP; GH receptor; serum binding protein; somatotropin receptor
Chromosomal Location5p14-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GHR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGHR
Namegrowth hormone receptor
Aliases growth hormone binding protein; GHIP; GH receptor; serum binding protein; somatotropin receptor
Chromosomal Location5p14-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GHR collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting GHR.
ID Name Drug Type Targets #Targets
DB00052SomatotropinBiotechGHR, PRLR2
DB00082PegvisomantBiotechGHR1
DB09098SomatremBiotechGHR, IGF1R2